
For research use only. We do not supply to patients.
For pharmaceutical-grade products or other inquiries, please contact our experts.
Miraziridine A is a cysteine protease inhibitor isolated from Theonella aff. mirabilis. The synthesis of miraziridine A involves the construction of a key building block, Fmoc-statine (Fmoc-Sta-OH). Starting from (3R,4S)-Boc-statine OEt, an inversion at the C-3 hydroxyl group using methanesulfonyl chloride gives a β-keto ester, followed by hydrolysis and Fmoc protection to yield Fmoc-Sta-OH. This protected statine derivative is then incorporated into a peptide chain assembled on solid support, using Fmoc-Abu-OH and Fmoc-Leu-OH via standard coupling reagents such as DIPC/HOBt. The tetrapeptide is elongated using EtO-Azd-OH with diphenylphosphoryl azide, and the final deprotection is achieved with porcine liver esterase to afford miraziridine A.
Fig. 1 FMOC-STA-OH for the synthesis of miraziridine A. (Alahmdi M. 2018)
References
Cat NO.: INT1264635655
CAS NO.: 1264635-65-5
Cat NO.: INT19592553
CAS NO.: 19592-55-3
Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed
All our products are chemicals for research purposes only. We do not supply for human or veterinary applications.
Privacy Policy | Cookie Policy Copyright © Protheragen. All Rights Reserved.
